Fenebrutinib delivers relapse control and MRI gains in late-stage multiple sclerosis trials
Roche’s investigational oral fenebrutinib is emerging as a serious contender in multiple sclerosis treatment after late-stage data showed both lower relapse activity and slower chronic lesion growth across relapsing and primary progressive disease. The drug reduced the annualized relapse rate by 55% versus teriflunomide over 96 weeks in pooled relapsing multiple sclerosis trials, a result that speaks to a strong anti-inflammatory effect in a disease driven by repeated immune attack on the central nervous system.
The signal was not limited to relapses. Across two relapsing trials and a third study in primary progressive multiple sclerosis, fenebrutinib also reduced the volume of slowly expanding lesions by up to 30% compared with teriflunomide or ocrelizumab. Those lesions matter because they represent chronic, smoldering inflammation inside the brain rather than the abrupt inflammatory bursts that usually define acute relapse activity. When a therapy slows that process, it suggests control beyond the visible flares that patients and clinicians often track first.
One of the more striking readouts came from the relapsing multiple sclerosis cohorts, where 75% of patients receiving fenebrutinib had no relapses, MRI activity, or worsening disability at nearly two years. That kind of composite disease control matters because it links three separate expressions of disease activity: clinical attacks, radiographic inflammation, and progression in function. A drug that reduces all three is doing more than suppressing symptoms; it is altering the inflammatory burden that accumulates over time.
Why slowly expanding lesions have become a more important target
Slowly expanding lesions have attracted increasing attention because they appear to reflect chronic compartmentalized inflammation within the brain. Unlike the classic enhancing lesion seen on MRI during active relapse, these lesions can expand quietly, often without obvious symptoms at the moment they develop. Their biology is part of what makes multiple sclerosis so difficult to control over the long run: inflammatory injury continues even when overt relapses become less frequent.
By reducing lesion volume growth, fenebrutinib appears to affect a disease process that sits closer to the center of long-term disability. That is especially relevant in progressive forms of multiple sclerosis, where the clinical challenge is not just stopping attacks but slowing the gradual deterioration that follows years of inflammatory damage. An oral therapy that can influence that pathway carries practical appeal, particularly for patients who may prefer a non-infusion option.
Fenebrutinib’s mechanism makes the result biologically plausible. As an investigational oral agent, it is being evaluated as a way to interrupt immune signaling that helps drive the B-cell activity implicated in multiple sclerosis. B-cell pathways are relevant in both relapsing and progressive disease, which helps explain why the drug is being studied across both phenotypes rather than being limited to one subtype.
The FDA review now places the drug in a high-stakes regulatory window
The U.S. Food and Drug Administration accepted Roche’s application for both relapsing and primary progressive multiple sclerosis under priority review in September. That regulatory status does not guarantee approval, but it does indicate that the submission is being handled on an accelerated timeline because of the potential clinical value of the therapy. The new efficacy data are being presented at the MSToronto2026 meeting and remain unpublished in a peer-reviewed journal.
For clinicians, the central question is whether the magnitude of benefit will translate into a useful place in treatment sequencing. Relapsing multiple sclerosis already has a crowded therapeutic field, and primary progressive disease remains one of the hardest domains in neurology to treat effectively. Any new oral option has to compete not only on efficacy but also on durability, safety, and the practicality of long-term use.
The comparison drugs also matter. Teriflunomide serves as an established oral comparator in relapsing disease, while ocrelizumab is one of the most important therapies in both relapsing and primary progressive multiple sclerosis. Showing activity against both comparators gives fenebrutinib a broader evidentiary footprint than a single-trial, single-phenotype result would have offered.
What the current data do and do not establish
The available evidence points to a compelling efficacy profile, but the presentation still leaves important clinical questions unanswered. The data have not yet appeared in a peer-reviewed journal, so the full methods, statistical handling, subgroup results, and safety detail remain outside the scope of the public summary. Without that level of granularity, it is impossible to weigh efficacy against tolerability with the same confidence clinicians would expect before adopting a new long-term therapy.
Safety will be especially important because multiple sclerosis treatment often spans years or decades. Patients and prescribers need to know whether an oral therapy that performs well on MRI and relapse endpoints can do so without introducing liver toxicity, infection risk, laboratory monitoring burdens, or other adverse effects that could limit real-world use. Those details will determine whether fenebrutinib is positioned as a preferred option or a more selective tool for specific patients.
The primary clinical appeal lies in the combination of outcomes: fewer relapses, less MRI activity, and slower chronic lesion expansion. In multiple sclerosis, where inflammation and neurodegeneration overlap, a therapy that pushes on both fronts has the potential to change how neurologists think about disease suppression. Yet the final judgment will depend on the full published dataset, the regulatory decision, and how the drug performs once it moves from trial populations into routine practice.